HTG-Induced Pancreatitis

### HTG-Induced Pancreatitis: Overview and Latest Treatments

**What is HTG-Induced Pancreatitis?**

HTG-induced pancreatitis refers to acute pancreatitis caused by severe hypertriglyceridemia (HTG), which is an abnormally high level of triglycerides in the blood. Triglycerides are a type of fat (lipid) found in the bloodstream, and their elevation can lead to inflammation of the pancreas.

Acute pancreatitis is a potentially life-threatening condition characterized by inflammation of the pancreas, causing abdominal pain, nausea, vomiting, and systemic complications. When triglyceride levels exceed 1,000 mg/dL (11.3 mmol/L) — and particularly when they surpass 2,000 mg/dL (22.6 mmol/L) — the risk of developing pancreatitis increases significantly. HTG is the third most common cause of acute pancreatitis after gallstones and alcohol.

**Pathophysiology:**

• In severe HTG, triglycerides in the blood are hydrolyzed by pancreatic lipase into free fatty acids (FFAs).
• Excess FFAs overwhelm the pancreas's buffering capacity, leading to toxic effects on pancreatic cells, local ischemia, and inflammation.
• This cascade of events results in acute pancreatitis.

---

### Risk Factors for HTG-Induced Pancreatitis:

1. **Genetic predisposition**: Familial hyperlipoproteinemia or mutations in genes like LPL, APOC2, APOA5, and GPIHBP1.

2. **Secondary causes**: Uncontrolled diabetes mellitus, obesity, metabolic syndrome, hypothyroidism, pregnancy, alcohol abuse, and certain medications (e.g., estrogens, isotretinoin, beta-blockers, or antiretrovirals).

3. **Diet**: High-fat diets can exacerbate the condition in susceptible individuals.

4. **Other factors**: Poorly controlled lipid-lowering therapy or nonadherence to treatment.

---

### Clinical Presentation:

• **Symptoms**: Severe epigastric pain radiating to the back, nausea, vomiting, and abdominal tenderness.
• **Lab findings**: Elevated serum triglycerides (often >1,000 mg/dL), elevated pancreatic enzymes (amylase and lipase), and evidence of systemic inflammation.
• **Imaging**: Abdominal CT or MRI may reveal pancreatic inflammation, necrosis, or fluid collections.

---

### Latest Treatment Strategies for HTG-Induced Pancreatitis:

• **Supportive Care**:
• **Fluid resuscitation**: Aggressive intravenous (IV) fluids (e.g., lactated Ringer's solution) to maintain hemodynamic stability and prevent complications.
• **Pain management**: Use of opioid analgesics (e.g., morphine or fentanyl) for severe abdominal pain.
• **Nutritional support**: Early enteral feeding (via nasogastric or nasojejunal tube) is preferred over parenteral nutrition to reduce the risk of infections and improve outcomes.

• **Monitoring and management of complications**:
• Monitor for systemic inflammatory response syndrome (SIRS), organ failure, and local complications (e.g., necrosis, abscess, or pseudocyst).
• Treat complications such as infected pancreatic necrosis with antibiotics or surgical intervention if needed.

---

#### 2. **Rapid Reduction of Triglycerides:**

The goal is to reduce triglyceride levels rapidly, ideally below 500 mg/dL, to mitigate ongoing pancreatic damage.

• **Insulin Infusion**:
• Insulin lowers triglycerides by activating lipoprotein lipase (LPL), which breaks down circulating triglycerides.
• Indicated in patients with concurrent diabetes, metabolic syndrome, or hyperglycemia.
• Dose: Continuous IV insulin infusion with glucose monitoring to prevent hypoglycemia.

• **Plasmapheresis (Therapeutic Plasma Exchange)**:
• Plasmapheresis is a procedure that removes triglyceride-rich plasma and replaces it with fresh plasma or albumin.
• It is considered in severe cases with extremely high triglycerides (>2,000 mg/dL) or when there is a poor response to medical therapy.
• Plasmapheresis can rapidly lower triglycerides and improve symptoms, but access to this therapy may be limited.

• **Heparin**:
• Low-dose unfractionated heparin can stimulate lipoprotein lipase activity and reduce triglycerides. However, its use is controversial due to the risk of bleeding and limited evidence supporting its efficacy.

---

#### 3. **Lipid-Lowering Medications:**

Once the acute phase is stabilized, long-term lipid-lowering therapy is initiated to prevent recurrence.

• **Fibrates** (e.g., fenofibrate, gemfibrozil):
• First-line agents for lowering triglycerides in patients with hypertriglyceridemia.
• They reduce hepatic production of triglycerides and increase triglyceride clearance.

• **Omega-3 Fatty Acids**:
• High-dose omega-3 fatty acids (e.g., 2-4 g/day of EPA/DHA) can effectively lower triglycerides.
• They are often used as an adjunct to fibrates or statins.

• **Statins**:
• While primarily used for cholesterol reduction, statins can modestly lower triglycerides and reduce cardiovascular risk.

• **Niacin**:
• Niacin (vitamin B3) reduces triglycerides by inhibiting hepatic triglyceride synthesis. However, its use is limited by side effects like flushing and hepatotoxicity.

---

#### 4. **Management of Underlying Conditions:**

• **Diabetes management**: Tight glycemic control with insulin or oral hypoglycemic agents.
• **Weight loss**: Lifestyle modifications, including weight loss and exercise, can reduce triglyceride levels.
• **Dietary changes**:
• Low-fat diet (<15% of total calories from fat).
• Avoid simple sugars, alcohol, and refined carbohydrates.
• **Alcohol cessation**: Essential for patients with alcohol-related HTG.

---

#### 5. **Experimental and Emerging Therapies:**

• **Gene Therapy**:
• Research is ongoing into gene therapies targeting mutations in genes like LPL and APOC3 to treat familial hypertriglyceridemia.
• **Apolipoprotein C-III (APOC3) Inhibitors**:
• Drugs like volanesorsen (an antisense oligonucleotide targeting APOC3) have shown promise in reducing triglycerides in patients with familial chylomicronemia syndrome (FCS).
• **ANGPTL3 Inhibitors**:
• Angiopoietin-like protein 3 (ANGPTL3) inhibitors (e.g., evinacumab) are being studied for their ability to lower triglycerides by enhancing lipoprotein lipase activity.

---

### Prognosis and Prevention:

• With prompt and appropriate management, most patients recover from HTG-induced pancreatitis without long-term complications.
• Preventive strategies include strict lipid control, lifestyle modifications, and adherence to medical therapy to prevent recurrence.

---

### Key Takeaways:

• HTG-induced pancreatitis is a serious condition requiring rapid diagnosis and treatment.
• Acute management focuses on supportive care and rapid triglyceride reduction using insulin infusions or plasmapheresis.
• Long-term management involves lipid-lowering therapies, lifestyle changes, and addressing underlying causes.
• Emerging therapies such as APOC3 and ANGPTL3 inhibitors hold promise for patients with severe or refractory hypertriglyceridemia.